Bo Ying

Money Moves

As of October 2026: Leading Abogen through its largest commercial deal

Novartis agreed to pay up to $7.8 billion for rights to Chinese biotech Abogen's mRNA therapeutics. The deal includes a $575 million upfront payment and an exclusive worldwide license to ABO2203, the first mRNA-encoded T-cell engager to reach clinical testing in autoimmune disease.

Updated Oct 2